


Korea's CorestemChemon expands global CRO reach with ATG Lifetech

21 July 2025 | News

Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery



CorestemChemon, a leading GLP-certified preclinical CRO based in South Korea, has entered into a strategic partnership with ATG Lifetech, a biotechnology startup specialising in transcriptome analytics and organoid-based modeling.

This collaboration aims to deliver next-generation, precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures across the US, Europe, and Asia.

Through this partnership, the two companies will co-develop:

- A transcriptome-based evaluation platform for predictive drug efficacy and safety profiling
- Disease-relevant organoid models for liver, heart, and the blood-brain barrier (BBB)
- A high-throughput transcriptomics analytics service for differentiating true vs. false positives in tumorigenicity studies
- Shared access to regulatory-aligned expertise for global clients targeting FDA/EMA pathways

Organoid-based assays are increasingly recognized for their translational advantage, offering up to 5x greater predictive accuracy in toxicity and efficacy screening compared to conventional 2D cell cultures, according to industry benchmarks. When integrated with whole-transcriptome analysis, these platforms enable earlier go/no-go decisions in drug pipelines, helping clients de-risk clinical entry and reduce overall development timelines.

The two companies plan to showcase their joint research outputs at a major toxicology and preclinical science conference in Q4 2025. Global service launches will follow, focused on biotech and pharmaceutical customers in need of high-content, biologically faithful preclinical testing.